Research Desk Line-up: Bio-Techne Post Earnings Coverage
LONDON, UK / ACCESSWIRE / November 8, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) ("Alexion"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/'symbol=ALXN. The Company announced on November 06, 2017, that it has received a new Patent, directed to the composition of matter of eculizumab (Soliris®) and pharmaceutical formulations of eculizumabby Japanese Patent Office (JPO), which will expire in 2027. For immediate access to our complimentary reports, including today's coverage, register for free now at:
http://protraderdaily.com/register/
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Bio-Techne Corporation (NASDAQ: TECH) for due-diligence and potential coverage as the Company reported on October 31, 2017, its financial results for Q1 FY18 which ended on September 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Bio-Techne when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on ALXN; also brushing on TECH. Go directly to your stock of interest and access today's free coverage at:
http://protraderdaily.com/optin/'symbol=ALXN
http://protraderdaily.com/optin/'symbol=TECH
The Company is pursuing corresponding patent applications in other regions and countries, including Europe. Alexion is also pursuing patent applications for pending additional indications of Soliris, such as for the treatment of refractory generalized myasthenia gravis (gMG).
What is Soliris® (Eculizumab)?
Soliris® (eculizumab) is a first-in-class terminal complement inhibitor discovered, developed, and commercialized by Alexion, and the world's first approved terminal complement inhibitor, for the treatment of patients with PNH, aHUS, and gMG. Alexion and Soliris have received some of the pharmaceutical industry's highest honors for the medical innovation in complement inhibition, the Prix Galien USA (2008, Best Biotechnology Product) and France (2009, Rare Disease Treatment).
Patent will Enhance Alexion's Global Portfolio of Intellectual Property Protection for Soliris
Ludwig Hantson, Chief Executive Officer of Alexion, stated that the Company is pleased that the JPO has granted an additional patent for Soliris, enhancing Alexion's global portfolio of intellectual property protection for this novel complement inhibitor. He added that the Company continues to serve patients in Japan and invest in additional research and development for Soliris®, and is also looking forward to work with other jurisdictions around the world to further strengthen its patent portfolio.
USPTO Issued Three US Patents for Soliris®
On August 15, 2017, the United States Patent and Trademark Office (USPTO) issued three US Patents, directed to the composition of matter of Soliris®, pharmaceutical formulations of eculizumab, and methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with eculizumab, respectively, which will expire in 2027.
The new composition of matter patent is directed to the full-length amino acid sequence of eculizumab and covers molecules that contain the same sequence. The new formulation patent is directed to pharmaceutical compositions that contain eculizumab, independent of their intended use. The new method of use patent is directed to treating PNH with eculizumab, and supplements other patents that are directed to treating atypical hemolytic uremic syndrome (aHUS) and other complement-mediated diseases with eculizumab.
FDA Approved Soliris for Treatment of Patients with gMG
The US Food and Drug Administration (FDA) approved Soliris® as a treatment for adult patients with gMG, who are anti-acetylcholine receptor (AchR) antibody-positive on October 23, 2017. In the Phase-3 REGAIN study and its ongoing open-label extension study, Soliris® demonstrated treatment benefits for patients with anti-AchR antibody-positive gMG who had previously failed immunosuppressive treatment and continued to suffer from significant unresolved disease symptoms.
About Alexion Pharmaceuticals, Inc.
Founded in 1992, Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. The Company's three highly innovative therapies treat patients with five severe and ultra-rare diseases. Headquartered in New Haven, Connecticut, Alexion employees around the world serve patients in approximately 50 countries.
Last Close Stock Review
On Tuesday, November 07, 2017, Alexion Pharma's stock closed the trading session at $117.42, climbing 1.28% from its previous closing price of $115.94. A total volume of 1.87 million shares were exchanged during the session, which was above the 3-month average volume of 1.76 million shares. Shares of the Company have a PE ratio of 52.49 and currently have a market cap of $26.18 billion.
Pro-Trader Daily:
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@protraderdaily.com
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily
